Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56. - Zou F; Lu L; Liu J; Xia B; Zhang W; Hu Q; Liu W; Zhang Y; Lin Y; Jing S; Huang M; Huang B; et al. (Nature communications, 2019)